Mesenchymal stem cell therapy - Bioinova

Drug Profile

Mesenchymal stem cell therapy - Bioinova

Alternative Names: AMSC; Autologous mesenchymal stem cell therapy - Bioinova

Latest Information Update: 26 Dec 2016

Price : $50

At a glance

  • Originator Bioinova
  • Class Antineoplastics; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Intervertebral disc degeneration; Shoulder injuries

Most Recent Events

  • 26 Dec 2016 Mesenchymal stem cell therapy is still in phase II trials for Intervertebral disc degeneration in Czech Republic (Bioinova website, December 2016)
  • 09 Oct 2014 Bioinova completes a phase II trial in Shoulder injuries (rotator-cuff tear) in Czech Republic (EudraCT2010-024664-17) prior to October 2014
  • 24 Aug 2013 Phase-II clinical trials in Intervertebral-disc-degeneration in Czech Republic (Parenteral) (EudraCT2010-024665-52)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top